D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2017
NCT03166189
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Active Ingredients

Drugs in Phase 4 Trials (2)

corifollitropin alfa (1 trial)

urofollitropin (Metrodin) (1 trial)

Drugs in Phase 2 Trials (1)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gynatresia (Phase 2)

Infertility (Phase 4)

Infertility, Female (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3